NCT06357494

Brief Summary

All cases of the study will be diagnosed as Graves' by History, examination, laboratory (FT3, FT4, TSH \& TRAbs), X-ray on left wrist for bone age, neck grey scale ultrasonography for thyroid gland size, shape, echotexture, vascularity and nodule characters if present with TIRAD score calculation. Then Color flow doppler ultrasound will be done to asses thyroid volume, number of vessels per square cm and inferior thyroid artery peak systolic velocity, end diastolic velocity and resistive index. Patients then will receive carbimazole antithyroid drug at dose 0.25-0.5 mg/kg/day PO \& the dose will be titrated according to thyroid function test after 4-6 weeks. Beta-adrenergic blockade will be added to all symptomatic cases. Regular follow up will be done every month of first 3 months of diagnosis and then every 3 months for 2 years by clinical and thyroid function test to asses response, compliance, complications, drug side effects, remission and relapses. Doppler ultrasound will be done at 0, 12 and 24 months.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P25-P50 for all trials

Timeline
24mo left

Started Aug 2024

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress48%
Aug 2024Apr 2028

First Submitted

Initial submission to the registry

April 5, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 10, 2024

Completed
4 months until next milestone

Study Start

First participant enrolled

August 5, 2024

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 5, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

April 5, 2028

Last Updated

July 16, 2024

Status Verified

July 1, 2024

Enrollment Period

2.7 years

First QC Date

April 5, 2024

Last Update Submit

July 14, 2024

Conditions

Outcome Measures

Primary Outcomes (5)

  • thyroid volume

    3 years

  • number of vessels per square cm of thyroid gland

    2 years

  • inferior thyroid artery peak systolic velocity

    2 years

  • end diastolic velocity

    2 years

  • resistive index

    2 years

Eligibility Criteria

Age1 Year - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodProbability Sample
Study Population

children who will come at pediatric endocrinology outpatient clinic of Assiut University Children's Hospital meeting our inclusion criteria.

You may qualify if:

  • All newly diagnosed children with clinical and laboratory hyperthyroidism (high T4 \& low TSH) with positive TRAbs.

You may not qualify if:

  • Patients receiving radioiodine Patients underwent thyroid surgery History of neck radiation or neck surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Graves Disease

Condition Hierarchy (Ancestors)

ExophthalmosOrbital DiseasesEye DiseasesGoiterThyroid DiseasesEndocrine System DiseasesHyperthyroidismAutoimmune DiseasesImmune System Diseases

Central Study Contacts

Hanaa A Mohamad, Professor of pediatrics

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant lecturer of pediatrics

Study Record Dates

First Submitted

April 5, 2024

First Posted

April 10, 2024

Study Start

August 5, 2024

Primary Completion (Estimated)

April 5, 2027

Study Completion (Estimated)

April 5, 2028

Last Updated

July 16, 2024

Record last verified: 2024-07